Insights › Likitanci da magunguna › November 17, 2026
Likitanci da magunguna · Ayyukan da ake kan yi da ci gaba

Inhibrx Ta Sanar da Sabbin Bayanan Asibiti na Ozekibart (INBRX-109) a Cikin Cutar Ewing Sarcoma

PR Newswire (Health) An wallafa: Results

- Hadin gwiwar Ozekibart a cutar Ewing Sarcoma wacce ta dawo ko kuma ba ta amsa magani ba ta samu kason ORR na 62.7%; - Kason DCR ya kai 86.3%, tare da ganin an samu amsa mai dorewa a marasa lafiya da suka sha wahala kafin su fara maganin SAN DIEGO, Nuwamba 17, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" ko kuma "Kamfanin"), wani kamfani da ke matakin gwajin asibiti...

Asalin tushe
Karanta tushen — prnewswire.com ↗

Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.

Ƙari a Likitanci da magunguna

Duba komai a cikin Likitanci da magunguna →

Ƙara bincika wannan batu

Karanta kowane bayani da yarenka

Wannan shafi yana nuna sabbin abubuwa uku ne kawai a kowane fanni. Mambobi na ganin kowane bayani a cikin fannin, a harsuna 109, tare da injinan bincike da ke aiki a kansu.

Karanta duka — fara daga $3Babu buƙatar shigarwa daga kantin manhajoji. Ana iya soke shi kowane lokaci.